Drugs.com

NOVEMBER 3, 2023

3, 2023 -- The first new antibiotic for gonorrhea — the second most common sexually transmitted disease — has shown promise in a clinical trial. FRIDAY, Nov. That news should come as a relief to public health experts, because gonorrhea.

Trials 317

Trials Clinical Trials Disease Drugs 317

BioPharma Drive: Drug Pricing

SEPTEMBER 6, 2024

New trial results could offer support for an expansion of Nucala’s label after U.S. regulators rejected GSK’s submission in 2018.

Trials 259

Trials Regulations Drugs 259

Drugs.com

DECEMBER 4, 2024

4, 2024 -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly."Given WEDNESDAY, Dec. Given the increased interest around obesity medications, we conducted.

Trials 279

Trials Clinical Trials Drugs 279

Drugs.com

OCTOBER 1, 2024

1, 2024 -- Clinical trials sponsored by Big Pharma enrolled eight times as many patients as U.S.-government government trials did between 2018 and 2022, new research shows.The study -- conducted by researchers at Fred Hutch Cancer Center in. TUESDAY, Oct.

Trials 242

Trials Clinical Trials Government Drugs 242

BioPharma Drive: Drug Pricing

AUGUST 29, 2024

The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion.

Trials 274

Trials Drugs 274

BioPharma Drive: Drug Pricing

JANUARY 30, 2024

The company plans to soon ask the FDA for approval of the drug, which it has pitched as a safer alternative to addictive opioid painkillers.

Trials 339

Trials FDA Drugs 339

BioPharma Drive: Drug Pricing

JUNE 20, 2024

Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.

Trials 284

Trials Doctors Drugs 284

Drugs.com

JUNE 24, 2024

MONDAY, June 24, 2024 -- Just two injections a year of a new HIV drug protected young women in Africa from infection with the sexually transmitted disease, new trial results show.In announcing the findings, Gilead Sciences Inc. said its HIV.

Trials 279

Trials Science Disease Drugs 279

PPD

JANUARY 15, 2025

As clinical trials become increasingly complex, particularly in decentralized trials and rare disease studies, sponsors experience increased challenges in site selection, forecasting and resourcing, and patient recruitment and enrollment. Discover how AI is used to optimize key aspects of clinical trial management. Get in touch.

Clinical Trials 95

Clinical Trials Trials Clinical Research Drug Development 95

BioPharma Drive: Drug Pricing

MARCH 29, 2024

Confirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set back.

Trials 300

Trials Drugs 300

BioPharma Drive: Drug Pricing

NOVEMBER 27, 2023

drugmaker withdrew the multiple myeloma drug from the U.S. One year after the U.K. market because of negative data, new study results might crack open the door to a relaunch.

Trials 284

Trials Drugs Marketing 284

BioPharma Drive: Drug Pricing

FEBRUARY 26, 2024

Zealand shares rose by more than one-third on the data, which provide further evidence so-called incretin drugs could help treat people with the liver disease.

Trials 293

Trials Drugs Disease 293

BioPharma Drive: Drug Pricing

APRIL 8, 2024

Underrepresentation of women in clinical trials affects the resulting drugs that become available later. Even small changes could boost participation.

Clinical Trials 293

Clinical Trials Trials Drugs 293

Drugs.com

FEBRUARY 4, 2025

Food and Drug Administration (FDA) has approved the first-ever clinical trials testing pig kidney transplants in people with kidney failure, marking a major step forward in cross-species transplantation.Two. TUESDAY, Feb. 4, 2025 -- The U.S.

Clinical Trials 244

Clinical Trials FDA Approval FDA Trials 244

BioPharma Drive: Drug Pricing

JUNE 26, 2024

The failure of a Phase 3 trial led the Wegovy maker to take an accounting charge that will hit its operating profit growth this year.

Trials 242

Trials Drugs 242

BioPharma Drive: Drug Pricing

MARCH 5, 2024

The study results further validate Roche’s recent decision to acquire rights to the drug, which is being developed for people with a stubborn form of hypertension.

Trials 301

Trials Drugs 301

Drugs.com

APRIL 9, 2025

WEDNESDAY, April 9, 2025 -- An experimental drug can help patients with advanced multiple sclerosis (MS) delay the progressive disability that comes with their disorder, a new clinical trial suggests.The drug, tolebrutinib, delayed disability.

Clinical Trials 268

Clinical Trials Drugs Trials 268

BioPharma Drive: Drug Pricing

MAY 16, 2024

Full study results disclosed ahead of a medical meeting showed elinzanetant consistently reduced the frequency and severity of hot flashes.

Trials 301

Trials Drugs 301

BioPharma Drive: Drug Pricing

APRIL 10, 2024

The company said the pause is necessary to meet regulatory limits on nitrosamine, but added it will not affect commercial supply nor regulatory review of the drug in early breast cancer.

Trials 293

Trials Drugs 293

Drug Target Review

DECEMBER 20, 2024

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

FDA Law Blog: Drug Discovery

JANUARY 30, 2025

However, as we note in that post, the design, timing of initiation, and timely conduct of confirmatory trials are also important considerations in FDAs determination of whether accelerated approval is appropriate. This blog post focuses on interpreting these new authorities with respect to timely conduct of confirmatory trials.

FDA 105

FDA Trials Disease Drugs 105

BioPharma Drive: Drug Pricing

DECEMBER 4, 2024

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

Drug Trials 313

Drug Trials Trials Treatment Marketing 313

BioPharma Drive: Drug Pricing

JULY 1, 2024

Study results are expected for a pair of closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.

Clinical Trials 339

Clinical Trials Trials Drugs 339

BioPharma Drive: Drug Pricing

FEBRUARY 15, 2024

Analysts pressed Alnylam executives on the reasons for the changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future.

Drug Trials 322

Drug Trials Trials Drugs 322

Drugs.com

JULY 18, 2024

THURSDAY, July 18, 2024 -- A new monoclonal antibody treatment called Kesimpta (ofatumumab) appears to improve on an older drug in pushing multiple sclerosis (MS) into remission, a new trial shows.Funded by Kesimpta's maker, Novartis, the trial.

Drugs 290

Drugs Trials Treatment 290

Science Daily: Pharmacology News

APRIL 8, 2025

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves neuron health in animal models of Alzheimer's disease, according to a new study.

Small Molecule 266

Small Molecule Disease Clinical Trials Drugs 266

BioPharma Drive: Drug Pricing

DECEMBER 20, 2024

Novo shares lost nearly a quarter of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.

Trials 300

Trials Treatment Drugs 300

Drugs.com

JULY 2, 2024

TUESDAY, July 2, 2024 -- A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday. In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early.

FDA Approval 290

FDA Approval Clinical Trials FDA Drugs 290

Science Daily: Pharmacology News

DECEMBER 10, 2023

Leukaemia trial shows 'exceptional' results. Personalized treatment for the most common form of adult leukemia helps patients survive for longer and stay in remission, a phase III trial has found.

Trials 217

Trials Treatment Disease Drugs 217

BioPharma Drive: Drug Pricing

JULY 15, 2024

Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.

Trials 322

Trials Drugs 322

Science Daily: Pharmacology News

APRIL 15, 2024

Researchers have discovered that an FDA-approved epilepsy drug can prevent or slow the growth of NF1-linked optic gliomas in mice, laying the groundwork for a clinical trial.

FDA Approval 329

FDA Approval Clinical Trials Drugs FDA 329

BioPharma Drive: Drug Pricing

JULY 22, 2024

The company plans to start a late-stage study next year, after a smaller trial found its drug offered “robust and consistent” benefits on communication, cognition and motor function.

Drugs 301

Drugs Trials 301

Science Daily: Pharmacology News

MARCH 19, 2025

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study.

Clinical Trials 307

Clinical Trials Drugs Trials Treatment 307

BioPharma Drive: Drug Pricing

APRIL 16, 2024

Shares of the biotech rose 25% after a large trial found adding its drug Caplyta onto antidepressant therapy significantly helped people with major depression.

Trials 196

Trials Drugs Therapies 196

BioPharma Drive: Drug Pricing

FEBRUARY 27, 2024

The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.

Drugs 313

Drugs Trials 313

BioPharma Drive: Drug Pricing

SEPTEMBER 17, 2024

Summary study results show Ascendis’ drug for achondroplasia could be competitive to BioMarin's Voxzogo, which is the foundation of the latter company's growth plans.

Trials 279

Trials Drugs 279